Explore

Trendline Trendline
Argenx Acquires Forte Biosciences for $2.2 Billion to Enhance Immunology Portfolio

Argenx Acquires Forte Biosciences for $2.2 Billion to Enhance Immunology Portfolio

Argenx Acquires Forte Biosciences for $2.2 Billion to Enhance Immunology Portfolio
Trendline Trendline
Yarrow Bioscience Completes Merger with VYNE Therapeutics, Advances Treatment for Thyroid Diseases

Yarrow Bioscience Completes Merger with VYNE Therapeutics, Advances Treatment for Thyroid Diseases

Yarrow Bioscience Completes Merger with VYNE Therapeutics, Advances Treatment for Thyroid Diseases
USA Today USA Today
Journey’s farewell tour continues with more than 30 concerts this fall

Journey’s farewell tour continues with more than 30 concerts this fall

Get ready to belt out "Don't Stop Believin'" one more time on Journey's farewell tour. Here's how to get tickets:
Cowboys Wire Cowboys Wire
‘Super Bowl or bust’ mindset good for Cowboys players, not for fans

‘Super Bowl or bust’ mindset good for Cowboys players, not for fans

When Dak Prescott said the expectations are "all or nothing" just like every year, he showed a major difference between Cowboys players and fans
SB Nation SB Nation
Will McClay reveals the truth behind the Cowboys roster decisions

Will McClay reveals the truth behind the Cowboys roster decisions

The Cowboys are a unique operation.
Eagles Wire Eagles Wire
Ranking all 6 NFC East first-round picks by potential for NFL success

Ranking all 6 NFC East first-round picks by potential for NFL success

Projecting NFL careers is never easy, but these six rookies appear poised to leave their mark in the NFC East and do so early.
Trendline Trendline
Argenx Acquires Forte Biosciences to Enhance Autoimmune Disease Portfolio

Argenx Acquires Forte Biosciences to Enhance Autoimmune Disease Portfolio

Argenx Acquires Forte Biosciences to Enhance Autoimmune Disease Portfolio
Trendline Trendline
Argenx Expands Immunology Portfolio with $2.2 Billion Acquisition of Forte Biosciences

Argenx Expands Immunology Portfolio with $2.2 Billion Acquisition of Forte Biosciences

Argenx Expands Immunology Portfolio with $2.2 Billion Acquisition of Forte Biosciences
Trendline Trendline
Argenx Acquires Forte Biosciences for $2.2 Billion to Expand Immunology Portfolio

Argenx Acquires Forte Biosciences for $2.2 Billion to Expand Immunology Portfolio

Argenx Acquires Forte Biosciences for $2.2 Billion to Expand Immunology Portfolio
Trendline Trendline
Yarrow Bioscience Completes Merger with VYNE Therapeutics and Begins Phase 2a/2b Trial for Graves' Disease Treatment

Yarrow Bioscience Completes Merger with VYNE Therapeutics and Begins Phase 2a/2b Trial for Graves' Disease Treatment

Yarrow Bioscience Completes Merger with VYNE Therapeutics and Begins Phase 2a/2b Trial for Graves' Disease Treatment
Trendline Trendline
Kirkland Ellis Expands Restructuring Group with Jones Day Partners in Dallas

Kirkland Ellis Expands Restructuring Group with Jones Day Partners in Dallas

Kirkland Ellis Expands Restructuring Group with Jones Day Partners in Dallas
Trendline Trendline
Dallas Leads U.S. Hotel Construction Pipeline with Record Projects and Rooms

Dallas Leads U.S. Hotel Construction Pipeline with Record Projects and Rooms

Dallas Leads U.S. Hotel Construction Pipeline with Record Projects and Rooms